Precision Medicine in AD: Castle’s Pipeline AD GEP Test May Help Patients Avoid Trial-and-Error Treatment Cycles
Castle Biosciences, Inc’s. pipeline atopic dermatitis (AD) test holds the potential to identify a subset of patients with AD who have an increased likelihood to achieve a super response to targeted therapies, indicated by a 90% or greater reduction in Eczema Area and Severity Index (EASI) score (EASI90) at three months. Assuming successful validation, Castle […]